Research
[Comment] Remibrutinib: a high-efficacy disease-modifying drug for relapsing multiple sclerosis?
The Lancet · By Gilles Edan & Emmanuelle Le Page ·
The Brief
- A Lancet comment asks whether remibrutinib, a BTK inhibitor, can be a high-efficacy disease-modifying drug for relapsing multiple sclerosis.
- BTK inhibitors directly modulate B lymphocytes and myeloid cells, including macrophages and microglia.
- Because they act on both adaptive and innate immune mechanisms, BTK inhibitors target two sides of MS immunopathology.
Why it matters
It reports on a possible new drug approach for relapsing multiple sclerosis, and science readers can track whether its mechanism translates into clinical efficacy.
Who’s affected
- people with relapsing multiple sclerosis
- neurologists and clinical MS researchers
- #multiple sclerosis
- #bruton tyrosine kinase
- #remibrutinib
- #neuroimmunology
- #disease-modifying therapy
Bruton's tyrosine kinase (BTK) inhibitors directly modulate the functions of B lymphocytes and myeloid cells (notably macrophages and microglia) and thus target both the adaptive and innate mechanisms that contribute to the immunopathology of multiple sclerosis on either side of…